Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 03 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rozanolixizumab (Primary)
Indications CNS demyelinating autoimmune diseases; Myelin oligodendrocyte glycoprotein antibody-associated disease
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms cosMOG
Sponsors UCB Biopharma; UCB Pharma Inc

03 Aug 2026 Planned number of patients changed from 110 to 125.
30 Jul 2026 According to UCB media release, topline data are currently planned for H2 2027
27 Feb 2026 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com